Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis Should We Stay or Should We Go?

Viewpoint stresses it is now time to focus more on individualised treatment strategies, especially on how to better predict which patients need therapy and which patients do not, at both the beginning of the disease and in older patients who have been treated for a long time.

Source:

JAMA Neurology